HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Cancer science - 111(2020), 9 vom: 10. Sept., Seite 3395-3396 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yoneshima, Yasuto [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.10.2020 Date Revised 28.10.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cas.14536 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311365639 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311365639 | ||
| 003 | DE-627 | ||
| 005 | 20231225142110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cas.14536 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1037.xml |
| 035 | |a (DE-627)NLM311365639 | ||
| 035 | |a (NLM)32557883 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yoneshima, Yasuto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.10.2020 | ||
| 500 | |a Date Revised 28.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a HTLV-I Antibodies |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Kato, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Minami, Haruna |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeda, Munehiko |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimoto, Goichi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Toshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Akashi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Yoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Okamoto, Isamu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer science |d 2003 |g 111(2020), 9 vom: 10. Sept., Seite 3395-3396 |w (DE-627)NLM12479498X |x 1349-7006 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2020 |g number:9 |g day:10 |g month:09 |g pages:3395-3396 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cas.14536 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2020 |e 9 |b 10 |c 09 |h 3395-3396 | ||